Literature DB >> 12213632

1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats.

Piotr Luchowski1, Elzbieta Luchowska, Waldemar A Turski, Ewa M Urbanska.   

Abstract

The aim of the present study was to evaluate the effect of mitochondrial inhibitors, 1-methyl-4-phenylpyridinium (MPP(+)) and 3-nitropropionic acid (3-NPA), on the brain production of endogenous glutamate antagonist, kynurenic acid (KYNA). MPP(+) and 3-NPA dose-dependently impaired the synthesis of KYNA in rat cortical slices. Enzymatic studies revealed that MPP(+) inhibits in a concentration-dependent manner the activity of kynurenine aminotransferase II (KAT II), but not the activity of kynurenine aminotransferase I (KAT I). 3-NPA impaired the activity of both enzymes, KAT I and KAT II. Thus, MPP(+)- and 3-NPA-evoked neurotoxicity may be at least partially associated with the depletion of KYNA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213632     DOI: 10.1016/s0304-3940(02)00735-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

1.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Authors:  Tomasz Kocki; Sebastian Wnuk; Renata Kloc; Janusz Kocki; Björn Owe-Larsson; Ewa M Urbanska
Journal:  J Neural Transm (Vienna)       Date:  2011-06-10       Impact factor: 3.575

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

3.  Novel aspect of ketone action: β-hydroxybutyrate increases brain synthesis of kynurenic acid in vitro.

Authors:  Iwona Chmiel-Perzyńska; Renata Kloc; Adam Perzyński; Sławomir Rudzki; Ewa M Urbańska
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

Review 4.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

Review 5.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

Review 6.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 7.  Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.

Authors:  Dénes Zádori; Levente Szalárdy; József Toldi; Ferenc Fülöp; Péter Klivényi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-11-30       Impact factor: 3.575

8.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

9.  The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing.

Authors:  Nóra Török; Rita Török; Zoltán Szolnoki; Ferenc Somogyvári; Péter Klivényi; László Vécsei
Journal:  Parkinsons Dis       Date:  2015-02-17

Review 10.  Kynurenines in CNS disease: regulation by inflammatory cytokines.

Authors:  Brian M Campbell; Erik Charych; Anna W Lee; Thomas Möller
Journal:  Front Neurosci       Date:  2014-02-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.